Primary Hepatic Neuroendocrine Carcinomas Treated with a Combination of Cisplatin and Etoposide as First-Line Chemotherapy: Two Case Reports Abstract #597

Introduction: Because primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare, a standard regimen has not yet been established. However, the combination of etoposide and cisplatin (EP) has been widely used to treat PHNEC.
Aim(s): We report two cases of PHNEC treated with EP and compare the efficacy of the EP regimen for PHNEC and pancreatic NEC (pNEC).
Materials and methods: We retrospectively analyzed the medical records of patients diagnosed with PHNEC and pNEC during January 2007–November 2012.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Shoichi Nakazuru

To read results and conclusion, please login ...

Further abstracts you may be interested in

#103 From hormone dependent solid breast carcinoma to primary neuroendocrine carcinoma: a case report
Introduction: Primary neuroendocrine carcinoma of the breast is an extremely rare tumor with incidence of 0.27-0.5%.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Djuro P Macut
Authors: Macut D, Kecman G, Bogavac T, Popovic B, ...
#117 Synchronous appendiceal neuroendocrine carcinoma and mucinous cystadenocarcinoma: a case report
Introduction: Appendiceal tumors with histological features of both carcinoids and adenocarcinomas are very rare. Carcinomas of the appendix are usually mucinous adenocarcinomas with a tendency to produce peritoneal pseudomyxoma and without metastatic spread until late in the disease course. Carcinoid tumors of the appendix are a common incidental finding.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
#632 Strategy of Combining Liver-directed Local Treatment with Systemic Treatment in Patients with Liver Metastasis of Neuroendocrine Tumor
Introduction: Little is known about the clinical outcomes of liver-directed local treatment (tx) in combination with systemic tx in patients with liver metastasis of neuroendocrine tumor (NET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Do-Youn Oh
Authors: Kim S, Kim J, Han S, Oh D Y, ...
#647 Reducing the Risk of Tuberculosis Reactivation when Administering Everolimus for a Pancreatic Neuroendocrine Tumor: A Case Report
Introduction: Everolimus can potentially reactivate tuberculosis (TB) through immunosuppression. This was recently reported to have occurred in a kidney transplant recipient. To date, no clear strategy has been developed for reducing the risk of TB reactivation during everolimus treatment.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: MD Takeshi Tamura
Keywords: everolimus, NET, LTBI